---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-005597"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2022-04-12T23:59:59+00:00"
generated_at: "2026-06-26T08:01:12.602561+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology appoints Dr. Itziar Canamasas to Board of Directors, effective April 11, 2022

## Summary
- Board size increased from six to seven directors; Canamasas appointed as Class II director with term expiring at 2022 Annual Meeting.
- Canamasas is Head of Oncology EMEA at Bayer AG with 20+ years of biopharma experience in commercialization and strategy.
- Granted initial stock option for 24,009 shares vesting monthly over three years, per director compensation policy.
- No arrangements or material transactions between Canamasas and the company other than standard indemnification agreement.

## SEC filing metadata
- accession: 0000950170-22-005597
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2022-04-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017022005597/0000950170-22-005597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017022005597/alxo-20220411.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-005597
- JSON: https://secwatch.observer/filing/0000950170-22-005597.json
- Plain text: https://secwatch.observer/filing/0000950170-22-005597.txt

## Key facts
- Executive change
  Itziar Canamasas was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
  - Action: appointed
  - Role: Director
  source text: Effective as of April 11, 2022, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Dr. Itziar Canamasas to its Board of Directors and increased the size of its Board of Directors from six to seven directors in connection with her appointment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017022005597/0000950170-22-005597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.